Sichuan Biosyn

Sichuan Biosyn is a China-based biopharmaceutical company focused on the discovery and development of innovative therapies for metabolic diseases, including type 2 diabetes and obesity. The company's lead programs primarily target the incretin system, utilizing small molecule and peptide-based approaches to improve glycemic control and weight management. Sichuan Biosyn maintains a robust research and development infrastructure in the Sichuan province, aiming to address the growing burden of metabolic disorders in the Asian market and beyond. Their pipeline includes several candidates in various stages of clinical and preclinical development, with a focus on high-potency and long-acting formulations.